GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vicapsys Life Sciences Inc (OTCPK:VICP) » Definitions » Retained Earnings

Vicapsys Life Sciences (Vicapsys Life Sciences) Retained Earnings : $-15.70 Mil (As of Sep. 2023)


View and export this data going back to . Start your Free Trial

What is Vicapsys Life Sciences Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Vicapsys Life Sciences's retained earnings for the quarter that ended in Sep. 2023 was $-15.70 Mil.

Vicapsys Life Sciences's quarterly retained earnings declined from Mar. 2023 ($-15.33 Mil) to Jun. 2023 ($-15.46 Mil) and declined from Jun. 2023 ($-15.46 Mil) to Sep. 2023 ($-15.70 Mil).

Vicapsys Life Sciences's annual retained earnings declined from Dec. 2020 ($-13.89 Mil) to Dec. 2021 ($-14.13 Mil) and declined from Dec. 2021 ($-14.13 Mil) to Dec. 2022 ($-15.12 Mil).


Vicapsys Life Sciences Retained Earnings Historical Data

The historical data trend for Vicapsys Life Sciences's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vicapsys Life Sciences Retained Earnings Chart

Vicapsys Life Sciences Annual Data
Trend Dec08 Dec09 Dec19 Dec20 Dec21 Dec22
Retained Earnings
Get a 7-Day Free Trial -5.91 -13.13 -13.89 -14.13 -15.12

Vicapsys Life Sciences Quarterly Data
Jun10 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14.63 -15.12 -15.33 -15.46 -15.70

Vicapsys Life Sciences Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Vicapsys Life Sciences  (OTCPK:VICP) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Vicapsys Life Sciences (Vicapsys Life Sciences) Business Description

Traded in Other Exchanges
N/A
Address
7778 Mcginnis Ferry Road, Suite 270, Suwanee, GA, USA, 30024
Vicapsys Life Sciences Inc is a biotech company that is engaged in commercializing implantable medical products that incorporate VICAPSYN, inducing a zone of immuno-protection around devices and cells implanted in the human body. The product name VICAPSYN is the company's line of proprietary product candidates that is applied to transplantation therapies and related stem-cell applications in the transplantation field.
Executives
Moore Bobby M Jr 10 percent owner 4125 S.B. MERRION ROAD, LAKELAND FL 33810
Robert Grammen 10 percent owner 9180 GALLENA COURT, NAPLES FL 34109
Michael Yurkowski director 1505 ELM STREET, #1504, DALLAS TX 75201
William P. Esping 10 percent owner 2828 ROUTH STREET, SUITE 500, DALLAS TX 75201
Rodger Rees director C/O BONDS.COM GROUP, INC., 1515 SOUTH FEDERAL HIGHWAY, SUITE 212, BOCA RATON FL 33432
Mark Feldmesser director 641 UNIVERSITY BLVE, JUPITER FL 33458
Federico Pier director 1004 PLUM DRIVE, IRVING TX 75063
Ryan Seddon director, 10 percent owner 8120 BELVEDERE ROAD, SUITE 4, WEST PALM BEACH FL 33411

Vicapsys Life Sciences (Vicapsys Life Sciences) Headlines

From GuruFocus